Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Frontiers in Oncology|June 26, 2020
Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural MesotheliomaRobert A Belderbos, Heleen Vroman, Joachim G J V Aerts
Molecular Therapy Oncolytics|April 26, 2019
Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional TreatmentRobert A Belderbos, Joachim G J V Aerts, Heleen Vroman
Translational Lung Cancer Research|September 21, 2020
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access programLuca Cantini, Robert A Belderbos, Cornedine J Gooijer, et al.
Translational Lung Cancer Research|August 2, 2019
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trialRobert A Belderbos, Paul Baas, Rossana Berardi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2020
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patientsLuca Cantini, Federica Pecci, Daan P Hurkmans, et al.
JTO Clinical and Research Reports|September 30, 2021
Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural MesotheliomaRobert A Belderbos, Alexander P W M Maat, Sara J Baart, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesotheliomaHeleen Vroman, Giulia Balzaretti, Robert A Belderbos, et al.
Thorax|February 12, 2022
Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based studyJob P van Kooten, Robert A Belderbos, Jan H von der Thüsen, et al.
Cell Reports. Medicine|February 16, 2023
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrumTetje C van der Sluis, Guillaume Beyrend, Esmé T I van der Gracht, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Pageof 2